The drug Lynparza was developed by AstraZeneca and Merck as a maintenance treatment for patients with a specific gene mutation whose cancer spread beyond the pancreas.
The newly-approved drug, sold under the brand name Zulresso, was shown to relieve depressive symptoms within hours of being administered in three different clinical trials and it continued to show success throughout their 30-day followups.
Esketamine is the first new drug treatment approved for depression in decades. Current drugs target the feel-good brain chemical serotonin, and can take weeks or months to kick in. Ketamine targets a chemical called glutamate that is thought to restore brain connections that help relieve depression.
The Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.